This website uses cookies so that we can provide you with the best user experience possible. Our Cookie Notice is part of our Privacy Policy and explains in detail how and why we use cookies. To take full advantage of our website, we recommend that you click on “Accept All”. You can change these settings at any time via the button "Update Cookie Preferences" in our Cookie Notice.
Technical cookies are required for the site to function properly, to be legally compliant and secure. Session cookies only last for the duration of your visit and are deleted from your device when you close your internet browser. Persistent cookies, however, remain and continue functioning on repeat visits.
CMS does not use any cookie based Analytics or tracking on our websites; see details here.
Personalisation cookies collect information about your website browsing habits and offer you a personalised user experience based on past visits, your location or browser settings. They also allow you to log in to personalised areas and to access third party tools that may be embedded in our website. Some functionality will not work if you don’t accept these cookies.
26/03/2010
Munich – Private equity investors Future Capital AG Hessen Life Sciences Chemie, Strategic European Technologies N.V. and HeidelbergCapital Private Equity Fund I GmbH & Co. KG and the company’s management have sold enzyme supplier IEP GmbH to US-based Cambrex Corporation.
A team from CMS Hasche Sigle led by lead partner Stefan-Ulrich Müller advised the three private equity investors and IEP management on all aspects of the transaction.
Prior to the sale, IEP GmbH was 100% owned by the three investor companies and management. Headquartered in Wiesbaden, the company is a leading global provider of innovative bio-catalytic processes and enzymes. IEP possesses outstanding interdisciplinary expertise in biochemistry, molecular biology and chemistry as well as a portfolio of more than 100 enzymes under patent protection. Using enzyme-based procedures, IEP optimises the manufacturing processes of low molecular weight active pharmaceutical ingredients.
New York Stock Exchange-listed Cambrex Corporation is a leading manufacturer of pharmaceutical substances and supplier of active ingredients and services to the life sciences industry. The company has research and production facilities in the US and Europe.
Advisers CMS Hasche Sigle:
Stefan-Ulrich Müller, Corporate (Lead Partner)
Jill Theuring, Corporate
Sebastian Wilhelm, Corporate
Roland Wutzke, Tax
Dr Martina Jentsch, Employment Law
Sylle Schreyer-Bestmann, IP
Sabine Korthaus, IP
Dr Stefan Segger, Insurance Law
Social Media cookies collect information about you sharing information from our website via social media tools, or analytics to understand your browsing between social media tools or our Social Media campaigns and our own websites. We do this to optimise the mix of channels to provide you with our content. Details concerning the tools in use are in our privacy policy.